Proinsulin-specific T regulatory cells may control immune responses in type 1 diabetes: implications for adoptive therapy

Abstract

ObjectiveHere we looked for possible mechanisms regulating the progression of type 1 diabetes mellitus (T1DM). In this disease, autoaggressive T cells (T conventional cells, Tconvs) not properly controlled by T regulatory cells (Tregs) destroy pancreatic islets.Research design and methodsWe compared the T-cell compartment of patients with newly diagnosed T1DM (NDT1DM) with long-duration T1DM (LDT1DM) ones. The third group consisted of patients with LDT1DM treated previously with polyclonal Tregs (LDT1DM with Tregs). We have also looked if the differences might be dependent on the antigen specificity of Tregs expanded for clinical use and autologous sentinel Tconvs.ResultsPatients with LDT1DM were characterized by T-cell immunosenescence-like changes and expansion of similar vβ/T-cell receptor (TCR) clones in Tconvs and Tregs. The treatment with Tregs was associated with some inhibition of these effects. Patients with LDT1DM possessed an increased percentage of various proinsulin-specific T cells but not GAD65-specific ones. The percentages of all antigen-specific subsets were higher in the expansion cultures than in the peripheral blood. The proliferation was more intense in proinsulin-specific Tconvs than in specific Tregs but the levels of some proinsulin-specific Tregs were exceptionally high at baseline and remained higher in the expanded clinical product than the levels of respective Tconvs in sentinel cultures.ConclusionsT1DM is associated with immunosenescence-like changes and reduced diversity of T-cell clones. Preferential expansion of the same TCR families in both Tconvs and Tregs suggests a common trigger/autoantigen responsible. Interestingly, the therapy with polyclonal Tregs was associated with some inhibition of these effects. Proinsulin-specific Tregs appeared to be dominant in the immune responses in patients with T1DM and probably associated with better control over respective autoimmune Tconvs.Trial registration numberEudraCT 2014-004319-35.

Antigenic Challenge Influences Epigenetic Changes in Antigen-Specific T Regulatory Cells

“…We found that antigen-specific Teffs could be generated with monocytes loaded with antigens, too. These results are important as they confirmed our in vivo data from type 1 diabetes in which we found that the disease-specific antigens can induce both specific Tregs and Teffs and the balance between these two subsets might be associated with the course of the disease (22). Importantly, current report confirms in vitro that the whole insulin is a poor stimulator of Tregs and the efficient induction of tolerance should be performed with other peptides, like b chain peptide 9-23.…”

Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy

“… 114 The complexity of the response is also caused by the fact that the same epitopes can trigger responses in both Tregs and Tconvs, and the final outcome depends on which subset prevails. 118 Nevertheless, there have been attempts to create Tregs with engineered TCRs to direct them to particular sites and protect particular organs from autoimmune attack. 119 These attempts for MS are at the EAE stage.…”

Exploiting Single-Cell Tools in Gene and Cell Therapy

“…In the context of diabetes, both CAR T cell and regulatory T cell (Tregs)-based treatments are currently being developed (141)(142)(143)(144)(145)(146). Under normal conditions, Tregs mediate immune tolerance by expressing anti-inflammatory cytokines and dampening the inflammatory or cytotoxic responses of other types of T lymphocytes (147).…”